Pyxis Oncology (PYXS) EBIT Margin (2024 - 2025)
Pyxis Oncology's (PYXS) quarterly EBIT Margin came in at 165.75% in Q4 2025, up 76.33% quarter-over-quarter from 700.35% in Q2 2025.
Powered by 
Analysis
Pyxis Oncology (PYXS) EBIT Margin (2024 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported EBIT Margin for 2 consecutive years, with 165.75% the latest figure, recorded in Q4 2025.
- On a quarterly basis, EBIT Margin changed N/A year-over-year to 165.75% in Q4 2025; TTM through Jun 2026 was 631.38%, a 314476.0% increase from a year earlier, with the FY2025 full-year figure at 609.18%, down 5511.0% from the prior year.
- EBIT Margin was 165.75% for Q4 2025 at Pyxis Oncology, up from 700.35% in the prior quarter.
- Over five years, EBIT Margin peaked at 34.71% in Q1 2024 and troughed at 700.35% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.74 Bn | 192.75 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.96 Bn | 176.78 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 131.20 Bn | 123.35 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 82.05 Bn | 74.05 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.08 Bn | 29.78 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.91 Bn | 30.62 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.22 Bn | 29.22 Bn | 1.16 Mn | -25,380.93% |
| 10 | Pyxis Oncology | 206.05 Mn | 173.06 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -165.75% |
| Jun 30, 2025 | -700.35% |
| Mar 31, 2024 | -34.71% |